eligard leuprorelin acetate 22.5mg modified release injection syringe
mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.
eligard leuprorelin acetate 7.5mg modified release injection syringe
mundipharma pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.1
lucrin depot 1-month
abbvie limited - leuprorelin acetate 3.75mg (powder for injection compartment) - injection (depot) - 3.75 mg - active: leuprorelin acetate 3.75mg (powder for injection compartment) excipient: acetic acid carmellose sodium gelatin plga (copoly (dl-lactic acid/glycolic acid) 75:25mol%) powder for injection compartment mannitol polysorbate 80 water for injection - lucrin (leuprorelin acetate) is indicated · in metastatic prostate cancer · in locally advanced prostate cancer, as an alternative to surgical castration · as an adjuvant treatment to radiotherapy in patients with high-risk localized or locally advanced prostate cancer · as an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression
lucrin depot 3-month
abbvie limited - leuprorelin acetate 11.25mg (powder for injection compartment) - injection (depot) - 11.25 mg - active: leuprorelin acetate 11.25mg (powder for injection compartment) excipient: carmellose sodium glacial acetic acid polylactic acid (pla) powder for injection compartment mannitol polysorbate 80 water for injection - lucrin (leuprorelin acetate) is indicated · in metastatic prostate cancer · in locally advanced prostate cancer, as an alternative to surgical castration · as an adjuvant treatment to radiotherapy in patients with high-risk localized or locally advanced prostate cancer · as an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression
lucrin depot 6-month
abbvie limited - leuprorelin acetate 30mg (powder for injection compartment) - injection (depot) - 30 mg - active: leuprorelin acetate 30mg (powder for injection compartment) excipient: carmellose sodium glacial acetic acid lactic acid mannitol polysorbate 80 water for injection - lucrin (leuprorelin acetate) is indicated · in metastatic prostate cancer · in locally advanced prostate cancer, as an alternative to surgical castration · as an adjuvant treatment to radiotherapy in patients with high-risk localized or locally advanced prostate cancer · as an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression
leptoprol 5mg implant in pre-filled syringe
1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - leuprorelin acetate - implant - leuprorelin acetate 5 mg - endocrine therapy
bi eligard cp (eligard 3 month 22.5mg and mpl-bicalutamide 50mg, 28 pack)
mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: polyglactin; n-methyl-2-pyrrolidone - bicalutamide,treatment of advanced prostate cancer in combination with lhrh agonist therapy.,leuprorelin,eligard? is indicated for the palliative treatment of advanced prostate cancer.
bi eligard cp (eligard 1 month 7.5mg and mpl-bicalutamide 50mg, 28 pack)
mundipharma pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - bicalutamide,treatment of advanced prostate cancer in combination with lhrh agonist therapy.,leuprorelin,eligard? is indicated for the palliative treatment of advanced prostate cancer.
bi eligard cp (eligard 3 month 22.5mg and mpl-bicalutamide 50mg, 84 pack)
mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - bicalutamide,treatment of advanced prostate cancer in combination with lhrh agonist therapy.,leuprorelin,eligard? is indicated for the palliative treatment of advanced prostate cancer.
leuprorelin sandoz implant in syringe 3.6 mg
sandoz singapore pte. ltd. - leuprorelin acetate eqv. leuprorelin - implant - leuprorelin acetate eqv. leuprorelin 3.6 mg